Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 5/20 | 0.59 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.56 |
| ▸ | FASN | P49327 | 2/20 | 0.49 |
| ▸ | VNN1 | O95497 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | CETP | P11597 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16616770 | 0.84 | NAMPT (0.67) | NAMPTEGLN1FASNVNN1 | |
| SCHEMBL13162880 | 0.82 | EGLN1 (0.55) | EGLN1FASN | |
| SCHEMBL13161992 | 0.81 | NAMPT (0.56) | NAMPTEGLN1FASNKDM1A | |
| SCHEMBL13162894 | 0.79 | HTR7 (0.60) | NAMPTHTR7CCR8 | |
| SCHEMBL29980802 | 0.79 | FASN (0.74) | FASN | |
| SCHEMBL12686841 | 0.79 | FASN (0.74) | FASN | |
| SCHEMBL24552383 | 0.75 | OPRM1 (0.59) | NAMPT | |
| SCHEMBL16110516 | 0.75 | EGLN1 (0.71) | EGLN1 | |
| SCHEMBL3709218 | 0.75 | NAMPT (1.00) | NAMPT | |
| SCHEMBL31431458 | 0.73 | KDM1A (0.42) | EGLN1KDM1ACETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | NAMPT 647/4885EGLN1 3941/4885FASN 4802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.